Ibrutinib linked to invasive fungal infections - CLL Support

CLL Support

23,088 members39,649 posts

Ibrutinib linked to invasive fungal infections

lankisterguy profile image
lankisterguyVolunteer
2 Replies

In the past Idelalisib (Zydelig) was found to increase the risk of Pneumocystis in previously untreated patients. Now Ibrutinib has also been linked, fortunately prophylaxis is available and risks may be evaluated based on CD-4 T-cell levels. Talk to your CLL specialist to make certain this has been thoroughly considered for you specific case.

-

By Neil Osterweil Publish date: March 7, 2018

Vitals FROM BLOOD

mdedge.com/hematologynews/n...

The tyrosine kinase inhibitor ibrutinib (Imbruvica) may be associated with early-onset invasive fungal infections (IFI) in patients with hematologic malignancies, investigators caution.

-

French investigators identified 33 cases of invasive fungal infections occurring among patients who had been treated with ibrutinib as monotherapy or in combination with other agents. Of the 33 cases, 27 were invasive aspergillosis, and 40% of these were localized in the central nervous system. The findings were published in the journal Blood.

-

“IFI tend to occur within the first months of treatment and are infrequent thereafter. Whilst it seems difficult at this point to advocate for systematic antifungal prophylaxis in all patients, an increased awareness about the potential risk of IFI after initiating ibrutinib is warranted, especially when other predisposing factors are associated,” wrote David Ghez, MD, PhD, and colleagues at the Gustave Roussy Institute in Villejuif and other centers in France.

-

Although ibrutinib, an inhibitor of Bruton’s tyrosine kinase, is generally considered to be less immunosuppressive than other therapies, it was associated with five cases of Pneumocystis jirovecii pneumonia in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib monotherapy in a 2016 report (Blood. 2016;128:1940-3). Of these five patients, four were treatment naive, suggesting that ibrutinib itself could increase risk for invasive opportunistic infections, Dr. Ghez and his colleagues noted.

-

If you are interested in reading more- see the box labeled "Related Posts" (top of right column on computer screens, way below on mobile devices).

Len

Written by
lankisterguy profile image
lankisterguy
Volunteer
To view profiles and participate in discussions please or .
Read more about...
2 Replies
Cllcanada profile image
CllcanadaTop Poster CURE Hero

Aspergillosis may be an issue too, but can't use antifungal prophelactic like voriconazole with Imbruvica (ibrutinib), since they are highly interactive...

~chris

Beattiem-UK profile image
Beattiem-UK in reply to Cllcanada

Is there anything we can do ourselves to minimise the risks of getting aspergillosis?

Not what you're looking for?

You may also like...

Possible Risk of Fungal Infection with Ibrutinib

It's just one case, but probably worth keeping in mind if you develop the symptoms. "In...

YABTKi or Yet Another BTK inhibitor - the A to Z list of Bruton's Tyrosine Kinase Inhibitors for CLL following Ibrutinib's success

I'll admit that YABTKi is not a recognised CLL related acronym, (acronym lists are here...

Clemastine (Tavegyl), an over-the-counter drug, found to be effective at inducing LMP and cell death

For what it may be worth, thougbt some of you might like to see this: "Lysosomes in chronic...

Relapsed CLL: New Approaches Prolong Survival

Dr Furman says that genetically unstable CLL patients need a combination therapy approach to...

BTK inhibitors for the treatment of CLL - the current state of play of 'brutinibs'

In just a short time, in many places, BTK inhibitors (BTKi) have largely replaced...